Contact:
Dean J. Paranicas/Investor Relations - 201-847-7102
Charles A. Borgognoni/Corporate Communications - 201-847-6651
BD ANNOUNCES RECORD FISCAL FOURTH QUARTER
AND FULL YEAR REVENUES
Franklin Lakes, NJ (November 6, 2002) - BD (Becton, Dickinson and Company)
(NYSE: BDX) today reported record quarterly revenues of $1.077 billion for the
fiscal fourth quarter ended September 30, 2002, an increase of 9 percent from
the same period a year ago. For the full year, the Company reported record
revenues of $4.033 billion, an 8 percent increase over a year ago.
Diluted earnings per share were 50 cents for the fourth quarter, which included
a charge of $13 million before taxes (recorded in "Other Expense") reflecting
the non-cash write-down of two equity investments resulting from a decline in
market values. Excluding the charge, diluted earnings per share would have been
53 cents. Diluted earnings per share for the full year of $1.79 also included
special charges recorded in the second and third quarters totaling 6 cents per
share, relating to the previously-announced manufacturing restructuring in the
BD Medical Systems segment.
Results for fiscal 2002 also reflected a 10 cent benefit from the adoption of
Statement of Financial Accounting Standards No. 142, "Goodwill and Other
Intangible Assets." Fiscal 2001 diluted earnings per share were 49 cents for the
fourth quarter and $1.49 for the full year, which included a charge in the
amount of 14 cents per share for the cumulative effect of an accounting change
recorded in connection with the Company's adoption of the Securities and
Exchange Commission's Staff Accounting Bulletin No. 101, "Revenue Recognition in
Financial Statements."
"Our strategies aimed at accelerating top line growth and driving productivity
are working. Revenue and earnings growth represent the achievement of the full
year performance objectives we had communicated to our shareholders at the
beginning of the year," said Edward J. Ludwig, Chairman, President and Chief
Executive Officer. "These results reflect solid revenue performance from all
three business segments, and in particular from our growth drivers.
Safety-engineered product sales grew 38 percent to $573 million, prefillable
drug delivery devices enjoyed a year of mid-teens growth, and BD Biosciences
closed the year strongly. Our strong cash flow continues to be driven by our
ongoing efforts to achieve greater operational effectiveness and even stronger
balance sheet productivity."
Segment Results
In the BD Medical Systems segment, worldwide revenues of $574 million increased
7 percent for the quarter. Included in these revenues were U.S.
safety-engineered product sales of $103 million, versus $78 million in the prior
year's quarter. Sales of safety-engineered products for the full year totaled
$353 million, versus $253 million in the prior year. Also contributing to the
growth of the segment were sales of prefillable drug delivery devices, which
grew 9 percent in the quarter and 17 percent for the full year. The overall
growth rate in the segment was partly offset by reduced sales of certain
conventional devices in the U.S. due to the transition to safety-engineered
devices.
In the BD Clinical Laboratory Solutions segment, worldwide revenues increased 11
percent for the quarter to $326 million. Revenue growth of 10 percent in the
Preanalytical Solutions portion of the segment was due to U.S. safety-engineered
product sales, which were $64 million, versus $50 million in the prior year's
quarter. Sales of safety-engineered products for the full year totaled $220
million, versus $163 million in the prior year. The overall growth rate of the
Preanalytical Solutions portion of the segment was partly offset by reduced
sales of certain conventional devices in the U.S. due to the transition to
safety-engineered devices. Also contributing to the segment's performance were
worldwide sales of the Diagnostic Systems portion of the segment, which
increased by 11 percent, driven by strong worldwide performance of its molecular
diagnostic platform, BD ProbeTec ET'TM'.
In the BD Biosciences segment, worldwide revenues grew 14 percent to $177
million for the quarter. Revenue growth was driven by strong sales of flow
cytometry instruments and reagents (Immunocytometry Systems), immunology/cell
biology reagents (Pharmingen), and Discovery Labware products. Molecular biology
reagent (Clontech) revenues of $18 million decreased by approximately $2 million
versus the prior year's quarter due to continued weakness in some portions of
the molecular biology market, largely due to softness in pharmaceutical/biotech
research and development spending, and a shift in pharmaceutical focus from
early stage drug target identification to later stage drug development. BD
Biosciences has refocused the Clontech research and development efforts toward
producing a product portfolio aligned with changing customer focus, and has
streamlined operations.
Geographic Results
On a geographic basis, fourth quarter revenues in the U.S. increased 8 percent
to $590 million. Revenues outside the U.S. of $487 million grew 10 percent, or 7
percent at constant foreign exchange rates. For the full year, revenues in the
U.S. increased 8 percent to $2.173 billion. Revenues of $1.860 billion outside
the U.S. increased by 8 percent, or 9 percent at constant foreign exchange
rates.
Fiscal 2003 Outlook
The Company confirmed its estimate of approximately $2.07 for diluted earnings
per share in fiscal 2003. The Company also indicated that it estimates first
quarter diluted earnings per share would approximate 39 cents. Included in first
quarter estimated diluted earnings per share are
approximately 2 cents of incremental costs associated with the anticipated U.S.
launch of the Company's blood glucose monitoring product.
BD is a medical technology company that serves healthcare institutions, life
science researchers, clinical laboratories, industry and the general public. BD
manufactures and sells a broad range of medical supplies, devices, laboratory
equipment and diagnostic products.
***
This press release may contain certain forward-looking statements (as defined
under Federal securities laws) regarding the Company's performance, including
future revenues, products and income, or events or developments that the Company
expects to occur or anticipates occurring in the future. All such statements are
based upon current expectations of the Company and involve a number of business
risks and uncertainties. Actual results could vary materially from anticipated
results described, implied or projected in any forward-looking statement.
Factors that could cause actual results to vary materially from any
forward-looking statement include, but are not limited to: competitive factors;
pricing and market share pressures; uncertainties of litigation; the Company's
ability to achieve sales and earnings forecasts, which are based on sales volume
and product mix assumptions, to achieve its cost savings objectives, and to
achieve anticipated synergies and other cost savings in connection with
acquisitions; changes in regional, national or foreign economic conditions;
increases in energy costs; fluctuations in costs and availability of raw
materials and in the Company's ability to maintain favorable supplier
arrangements and relationships; changes in interest or foreign currency exchange
rates; delays in product introductions; and changes in health care or other
governmental regulation, as well as other factors discussed in this press
release and in the Company's filings with the Securities and Exchange
Commission. We do not intend to update any forward-looking statements.
***
BD's news releases can be found on its website at www.bd.com or through Business
Wire at www.businesswire.com. A conference call with analysts regarding this
news release will be broadcast live on BD's website at 8:30 a.m. EST Thursday,
November 7, 2002. The conference call will be available for playback on BD's
website or at 1-888-562-0218 (domestic) and 1-402-998-1407 (international)
through the close of business on November 14, 2002.
BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)
Three Months Ended September 30,
2002 2001 % Change
- ----------------------------------------------------------------------------------
REVENUES $1,076,692 $987,525 9.0
Cost of products sold 546,703 497,745 9.8
Selling and administrative 282,232 257,383 9.7
Research and development 55,598 51,505 7.9
- ----------------------------------------------------------------------------------
TOTAL OPERATING COSTS
AND EXPENSES 884,533 806,633 9.7
- ----------------------------------------------------------------------------------
OPERATING INCOME 192,159 180,892 6.2
Interest expense, net (6,216) (7,697) (19.2)
Other (expense) income, net (13,959) 30 NM
- ----------------------------------------------------------------------------------
INCOME BEFORE
INCOME TAXES 171,984 173,225 (0.7)
Income tax provision 40,588 40,815 (0.6)
- ----------------------------------------------------------------------------------
NET INCOME $ 131,396 $132,410 (0.8)
- ----------------------------------------------------------------------------------
EARNINGS PER SHARE
Basic $ 0.51 $ 0.51 -
Diluted $ 0.50 $ 0.49 2.0
- ----------------------------------------------------------------------------------
AVERAGE SHARES OUTSTANDING
Basic 256,376 258,952
Diluted 264,091 270,376
- ----------------------------------------------------------------------------------
NM - Not Meaningful
See Note to Consolidated Income Statements.
Page 1
BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)
Twelve Months Ended September 30,
2002 2001 % Change
- ----------------------------------------------------------------------------------
REVENUES $4,033,069 $3,746,182 7.7
Cost of products sold 2,083,669 1,913,292 8.9
Selling and administrative 1,032,043 983,296 5.0
Research and development 220,186 211,834 3.9
Special charges 21,508 - NM
- ----------------------------------------------------------------------------------
TOTAL OPERATING COSTS
AND EXPENSES 3,357,406 3,108,422 8.0
- ----------------------------------------------------------------------------------
OPERATING INCOME 675,663 637,760 5.9
Interest expense, net (33,304) (55,414) (39.9)
Other expense, net (13,770) (5,596) NM
- ----------------------------------------------------------------------------------
INCOME BEFORE
INCOME TAXES 628,589 576,750 9.0
Income tax provision 148,607 138,348 7.4
- ----------------------------------------------------------------------------------
INCOME BEFORE
CUMULATIVE EFFECT OF
CHANGE IN ACCOUNTING
PRINCIPLE, NET OF TAX 479,982 438,402 9.5
Cumulative effect, net of tax - (36,750) NM
- ----------------------------------------------------------------------------------
NET INCOME $ 479,982 $ 401,652 19.5
- ----------------------------------------------------------------------------------
BASIC EARNINGS PER SHARE
Before Cumulative Effect $ 1.85 $ 1.69 9.5
Cumulative Effect - (0.14) NM
- ----------------------------------------------------------------------------------
Basic Earnings Per Share $ 1.85 $ 1.55 NM
- ----------------------------------------------------------------------------------
DILUTED EARNINGS PER SHARE
Before Cumulative Effect $ 1.79 $ 1.63 9.8
Cumulative Effect - (0.14) NM
- ----------------------------------------------------------------------------------
Diluted Earnings Per Share $ 1.79 $ 1.49 NM
- ----------------------------------------------------------------------------------
AVERAGE SHARES OUTSTANDING
Basic 258,016 257,128
Diluted 268,183 268,833
- ----------------------------------------------------------------------------------
NM - Not Meaningful
See Note to Consolidated Income Statements.
Page 2
BECTON DICKINSON AND COMPANY
NOTE TO CONSOLIDATED INCOME STATEMENTS
Twelve Months Ended September 30, 2002
Fiscal 2002 revenues included hedging costs of approximately $3.6 million for
the fourth quarter and $10.6 million for the twelve months, compared with $1.3
million and $9.9 million, respectively, in fiscal 2001. These costs related to
BD's purchased option contracts to hedge a portion of its anticipated sales from
the United States to non-U.S. customers. Hedging costs of approximately $8.1
million for the first six months of fiscal 2001 were recorded in Other Expense
under previous accounting guidance. This amount has been reclassed to revenues.
Also included in revenues were losses on forward contracts of approximately $0.9
million for the fourth quarter and net gains on purchased option and forward
contracts of approximately $3.5 million for the twelve months, compared with
gains of $4.2 million and $12.4 million, respectively, in fiscal 2001.
Page 3
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)
Three Months Ended September 30,
2002 2001 % Change
-------------------------------------------
MEDICAL SYSTEMS
United States $ 300,433 $ 281,652 6.7
International 273,351 255,643 6.9
- ----------------------------------------------------------------------------------
TOTAL $ 573,784 $ 537,295 6.8
- ----------------------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
United States $ 194,747 $ 175,719 10.8
International 131,136 119,306 9.9
- ----------------------------------------------------------------------------------
TOTAL $ 325,883 $ 295,025 10.5
- ----------------------------------------------------------------------------------
BIOSCIENCES
United States $ 94,574 $ 87,878 7.6
International 82,451 67,327 22.5
- ----------------------------------------------------------------------------------
TOTAL $ 177,025 $ 155,205 14.1
- ----------------------------------------------------------------------------------
TOTAL REVENUES
United States $ 589,754 $ 545,249 8.2
International 486,938 442,276 10.1
- ----------------------------------------------------------------------------------
TOTAL $1,076,692 $ 987,525 9.0
- ----------------------------------------------------------------------------------
Twelve Months Ended September 30,
2002 2001 % Change
-------------------------------------------
MEDICAL SYSTEMS
United States $1,092,428 $1,007,601 8.4
International 1,058,946 997,025 6.2
- ----------------------------------------------------------------------------------
TOTAL $2,151,374 $2,004,626 7.3
- ----------------------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
United States $ 735,613 $ 679,880 8.2
International 500,706 471,637 6.2
- ----------------------------------------------------------------------------------
TOTAL $1,236,319 $1,151,517 7.4
- ----------------------------------------------------------------------------------
BIOSCIENCES
United States $ 344,853 $ 329,042 4.8
International 300,523 260,997 15.1
- ----------------------------------------------------------------------------------
TOTAL $ 645,376 $ 590,039 9.4
- ----------------------------------------------------------------------------------
TOTAL REVENUES
United States $2,172,894 $2,016,523 7.8
International 1,860,175 1,729,659 7.5
- ----------------------------------------------------------------------------------
TOTAL $4,033,069 $3,746,182 7.7
- ----------------------------------------------------------------------------------
Page 4
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Three Months Ended September 30,
(Unaudited; Amounts in thousands)
United States
-------------------------------------------
2002 2001 % Change
-------------------------------------------
MEDICAL SYSTEMS
Medical Surgical $199,340 $178,590 11.6
Consumer Health Care 75,295 77,349 (2.7)
Pharmaceutical Systems 20,295 19,142 6.0
Ophthalmic Systems 5,503 6,571 (16.3)
- ----------------------------------------------------------------------------------
TOTAL $300,433 $281,652 6.7
- ----------------------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
Preanalytical Solutions $106,364 $ 95,734 11.1
Diagnostic Systems 88,383 79,985 10.5
- ----------------------------------------------------------------------------------
TOTAL $194,747 $175,719 10.8
- ----------------------------------------------------------------------------------
BIOSCIENCES
Discovery Labware 27,050 22,859 18.3
Immunocytometry & Reagents:
Flow Cytometry Instruments
& Reagents 36,249 33,584 7.9
Molecular Biology Reagents 12,960 15,298 (15.3)
Immunology/Cell Biology Reagents 18,315 16,137 13.5
- ----------------------------------------------------------------------------------
Total Immunocytometry & Reagents 67,524 65,019 3.9
- ----------------------------------------------------------------------------------
TOTAL $ 94,574 $ 87,878 7.6
- ----------------------------------------------------------------------------------
TOTAL UNITED STATES $589,754 $545,249 8.2
- ----------------------------------------------------------------------------------
International
-------------------------------------------
2002 2001 % Change
-------------------------------------------
MEDICAL SYSTEMS
Medical Surgical $153,184 $146,435 4.6
Consumer Health Care 48,236 44,804 7.7
Pharmaceutical Systems 64,448 58,300 10.5
Ophthalmic Systems 7,483 6,104 22.6
- ----------------------------------------------------------------------------------
TOTAL $273,351 $255,643 6.9
- ----------------------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
Preanalytical Solutions $ 64,910 $ 60,355 7.5
Diagnostic Systems 66,226 58,951 12.3
- ----------------------------------------------------------------------------------
TOTAL $131,136 $119,306 9.9
- ----------------------------------------------------------------------------------
BIOSCIENCES
Discovery Labware 18,662 16,339 14.2
Immunocytometry & Reagents:
Flow Cytometry Instruments
& Reagents 46,787 37,752 23.9
Molecular Biology Reagents 5,083 4,382 16.0
Immunology/Cell Biology Reagents 11,919 8,854 34.6
- ----------------------------------------------------------------------------------
Total Immunocytometry & Reagents 63,789 50,988 25.1
- ----------------------------------------------------------------------------------
TOTAL $ 82,451 $ 67,327 22.5
- ----------------------------------------------------------------------------------
TOTAL INTERNATIONAL $486,938 $442,276 10.1
- ----------------------------------------------------------------------------------
Page 5
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)
Total
-------------------------------------------
2002 2001 % Change
-------------------------------------------
MEDICAL SYSTEMS
Medical Surgical $ 352,524 $ 325,025 8.5
Consumer Health Care 123,531 122,153 1.1
Pharmaceutical Systems 84,743 77,442 9.4
Ophthalmic Systems 12,986 12,675 2.5
- ----------------------------------------------------------------------------------
TOTAL $ 573,784 $ 537,295 6.8
- ----------------------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
Preanalytical Solutions $ 171,274 $ 156,089 9.7
Diagnostic Systems 154,609 138,936 11.3
- ----------------------------------------------------------------------------------
TOTAL $ 325,883 $ 295,025 10.5
- ----------------------------------------------------------------------------------
BIOSCIENCES
Discovery Labware 45,712 39,198 16.6
Immunocytometry & Reagents:
Flow Cytometry Instruments
& Reagents 83,036 71,336 16.4
Molecular Biology Reagents 18,043 19,680 (8.3)
Immunology/Cell Biology Reagents 30,234 24,991 21.0
- ----------------------------------------------------------------------------------
Total Immunocytometry & Reagents 131,313 116,007 13.2
- ----------------------------------------------------------------------------------
TOTAL $ 177,025 $ 155,205 14.1
- ----------------------------------------------------------------------------------
TOTAL REVENUES $1,076,692 $ 987,525 9.0
- ----------------------------------------------------------------------------------
FX Neutral % Growth
-------------------------------
International Total
--------------- ---------------
MEDICAL SYSTEMS
Medical Surgical 3.5 8.0
Consumer Health Care 5.5 0.3
Pharmaceutical Systems 2.1 3.1
Ophthalmic Systems 17.5 -
- ----------------------------------------------------------------------
TOTAL 3.9 5.3
- ----------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
Preanalytical Solutions 3.3 8.1
Diagnostic Systems 9.8 10.2
- ----------------------------------------------------------------------
TOTAL 6.5 9.1
- ----------------------------------------------------------------------
BIOSCIENCES
Discovery Labware 11.3 15.4
Immunocytometry & Reagents:
Flow Cytometry Instruments
& Reagents 19.8 14.2
Molecular Biology Reagents 6.9 (10.3)
Immunology/Cell Biology Reagents 25.9 17.9
- ----------------------------------------------------------------------
Total Immunocytometry & Reagents 19.8 10.8
- ----------------------------------------------------------------------
TOTAL 17.7 12.0
- ----------------------------------------------------------------------
TOTAL 6.7 7.5
- ----------------------------------------------------------------------
Page 6
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Twelve Months Ended September 30,
(Unaudited; Amounts in thousands)
United States
-------------------------------------------
2002 2001 % Change
-------------------------------------------
MEDICAL SYSTEMS
Medical Surgical $ 720,593 $ 630,666 14.3
Consumer Health Care 275,643 291,371 (5.4)
Pharmaceutical Systems 71,122 57,606 23.5
Ophthalmic Systems 25,070 27,958 (10.3)
- ----------------------------------------------------------------------------------
TOTAL $1,092,428 $1,007,601 8.4
- ----------------------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
Preanalytical Solutions $ 383,482 $ 345,699 10.9
Diagnostic Systems 352,131 334,181 5.4
- ----------------------------------------------------------------------------------
TOTAL $ 735,613 $ 679,880 8.2
- ----------------------------------------------------------------------------------
BIOSCIENCES
Discovery Labware 99,595 89,828 10.9
Immunocytometry & Reagents:
Flow Cytometry Instruments
& Reagents 124,327 119,929 3.7
Molecular Biology Reagents 54,203 60,707 (10.7)
Immunology/Cell Biology Reagents 66,728 58,578 13.9
- ----------------------------------------------------------------------------------
Total Immunocytometry & Reagents 245,258 239,214 2.5
- ----------------------------------------------------------------------------------
TOTAL $ 344,853 $ 329,042 4.8
- ----------------------------------------------------------------------------------
TOTAL UNITED STATES $2,172,894 $2,016,523 7.8
- ----------------------------------------------------------------------------------
International
-------------------------------------------
2002 2001 % Change
-------------------------------------------
MEDICAL SYSTEMS
Medical Surgical $ 591,782 $ 567,845 4.2
Consumer Health Care 185,036 185,511 (0.3)
Pharmaceutical Systems 255,224 220,703 15.6
Ophthalmic Systems 26,904 22,966 17.1
- ----------------------------------------------------------------------------------
TOTAL $1,058,946 $ 997,025 6.2
- ----------------------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
Preanalytical Solutions $ 253,712 $ 238,578 6.3
Diagnostic Systems 246,994 233,059 6.0
- ----------------------------------------------------------------------------------
TOTAL $ 500,706 $ 471,637 6.2
- ----------------------------------------------------------------------------------
BIOSCIENCES
Discovery Labware 68,228 61,463 11.0
Immunocytometry & Reagents:
Flow Cytometry Instruments
& Reagents 170,391 145,436 17.2
Molecular Biology Reagents 18,507 17,900 3.4
Immunology/Cell Biology Reagents 43,397 36,198 19.9
- ----------------------------------------------------------------------------------
Total Immunocytometry & Reagents 232,295 199,534 16.4
- ----------------------------------------------------------------------------------
TOTAL $ 300,523 $ 260,997 15.1
- ----------------------------------------------------------------------------------
TOTAL INTERNATIONAL $1,860,175 $1,729,659 7.5
- ----------------------------------------------------------------------------------
Page 7
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)
Total
-------------------------------------------
2002 2001 % Change
-------------------------------------------
MEDICAL SYSTEMS
Medical Surgical $1,312,375 $1,198,511 9.5
Consumer Health Care 460,679 476,882 (3.4)
Pharmaceutical Systems 326,346 278,309 17.3
Ophthalmic Systems 51,974 50,924 2.1
- ----------------------------------------------------------------------------------
TOTAL $2,151,374 $2,004,626 7.3
- ----------------------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
Preanalytical Solutions $ 637,194 $ 584,277 9.1
Diagnostic Systems 599,125 567,240 5.6
- ----------------------------------------------------------------------------------
TOTAL $1,236,319 $1,151,517 7.4
- ----------------------------------------------------------------------------------
BIOSCIENCES
Discovery Labware 167,823 151,291 10.9
Immunocytometry & Reagents:
Flow Cytometry Instruments
& Reagents 294,718 265,365 11.1
Molecular Biology Reagents 72,710 78,607 (7.5)
Immunology/Cell Biology Reagents 110,125 94,776 16.2
- ----------------------------------------------------------------------------------
Total Immunocytometry & Reagents 477,553 438,748 8.8
- ----------------------------------------------------------------------------------
TOTAL $ 645,376 $ 590,039 9.4
- ----------------------------------------------------------------------------------
TOTAL REVENUES $4,033,069 $3,746,182 7.7
- ----------------------------------------------------------------------------------
FX Neutral % Growth
-------------------------------
International Total
--------------- ---------------
MEDICAL SYSTEMS
Medical Surgical 6.3 10.5
Consumer Health Care 1.1 (2.9)
Pharmaceutical Systems 14.2 16.1
Ophthalmic Systems 17.5 2.2
- ----------------------------------------------------------------------
TOTAL 7.3 7.9
- ----------------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
Preanalytical Solutions 6.6 9.2
Diagnostic Systems 7.9 6.4
- ----------------------------------------------------------------------
TOTAL 7.3 7.8
- ----------------------------------------------------------------------
BIOSCIENCES
Discovery Labware 13.4 11.9
Immunocytometry & Reagents:
Flow Cytometry Instruments
& Reagents 18.3 11.7
Molecular Biology Reagents 1.1 (8.0)
Immunology/Cell Biology Reagents 19.2 15.9
- ----------------------------------------------------------------------
Total Immunocytometry & Reagents 17.0 9.1
- ----------------------------------------------------------------------
TOTAL 16.1 9.8
- ----------------------------------------------------------------------
TOTAL 8.6 8.2
- ----------------------------------------------------------------------
Page 8